Sudarshan Pharma Industries Ltd

Sudarshan Pharma Industries Ltd

₹ 402 -2.07%
07 Nov - close price
About

Incorporated in 2008, Mumbai-based Sudarshan Pharma Industries Limited (SPIL) has a contract manufacturing facility for generic formulations. It is also engaged in import & export activities, and supply of specialty chemicals, API, and Intermediates[1]

Key Points

Business Area
A) Specialty Chemicals, Intermediates & API[1] Co. is involved in Manufacturing, Imports of specialty chemicals & exports, as well as outsourcing & Supply of Specialty chemicals, bulk drugs, and API for domestic and international clients in Pharma, agrochemicals, Paints, resins & various industry.

  • Market Cap 969 Cr.
  • Current Price 402
  • High / Low 453 / 58.2
  • Stock P/E 72.4
  • Book Value 48.9
  • Dividend Yield 0.00 %
  • ROCE 13.8 %
  • ROE 10.8 %
  • Face Value 10.0

Pros

Cons

  • Stock is trading at 8.23 times its book value
  • Company has a low return on equity of 12.1% over last 3 years.
  • Debtor days have increased from 78.7 to 96.5 days.
  • Working capital days have increased from 87.0 days to 137 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Sector: Trading Industry: Trading

Loading peers table ...

Half Yearly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Mar 2023 Sep 2023 Mar 2024 Sep 2024
195 266 232 232 228
189 258 223 217 211
Operating Profit 7 8 8 14 17
OPM % 4% 3% 4% 6% 7%
0 1 2 1 0
Interest 2 3 3 6 8
Depreciation 0 0 1 1 1
Profit before tax 5 5 7 9 8
Tax % 25% 26% 26% 24% 26%
4 4 5 7 6
EPS in Rs 3.25 1.47 2.02 2.74 2.46
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 TTM
148 193 357 461 464 460
143 186 346 446 441 429
Operating Profit 5 7 11 15 23 31
OPM % 3% 4% 3% 3% 5% 7%
0 0 0 1 3 1
Interest 3 3 3 5 9 13
Depreciation 0 1 1 1 1 2
Profit before tax 2 4 7 9 15 17
Tax % 26% 25% 26% 26% 25%
1 3 5 7 11 13
EPS in Rs 1.34 2.80 5.39 2.93 4.76 5.20
Dividend Payout % 0% 0% 0% 10% 0%
Compounded Sales Growth
10 Years: %
5 Years: %
3 Years: 34%
TTM: -8%
Compounded Profit Growth
10 Years: %
5 Years: %
3 Years: 63%
TTM: 60%
Stock Price CAGR
10 Years: %
5 Years: %
3 Years: %
1 Year: 406%
Return on Equity
10 Years: %
5 Years: %
3 Years: 12%
Last Year: 11%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Sep 2024
Equity Capital 10 10 10 24 24 24
Reserves 10 13 20 77 88 94
21 30 31 34 105 124
18 47 77 97 67 78
Total Liabilities 58 99 138 232 283 320
6 6 6 20 26 25
CWIP 0 0 1 0 2 2
Investments 0 0 0 12 14 30
53 93 131 200 242 263
Total Assets 58 99 138 232 283 320

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
1 3 -4 -29 6
-3 -1 -1 -26 -5
-0 -1 4 66 -12
Net Cash Flow -2 -0 -1 11 -12

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Debtor Days 66 114 75 64 96
Inventory Days 46 49 51 63 74
Days Payable 40 91 80 78 49
Cash Conversion Cycle 72 72 46 50 122
Working Capital Days 69 69 54 71 137
ROCE % 15% 19% 15% 14%

Shareholding Pattern

Numbers in percentages

28 Recently
Mar 2023Sep 2023Mar 2024Sep 2024
57.39% 57.39% 57.39% 57.39%
3.58% 1.40% 1.40% 13.07%
39.02% 41.20% 41.21% 29.54%
No. of Shareholders 1,244983913787

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents